Under the Protecting Access to Medicare Act (PAMA), Congress changed the way Medicare determines rates for the Clinical Laboratory Fee Schedule (CLFS), and the implementation of PAMA led to a significant cut for a majority of the routine tests relied upon every day in the diagnosis and treatment of patients. Concerned about the impact of cuts on patient access to testing, COLA Inc. has gathered data on the impact of these cuts on clinical laboratories over the last three years with surveys conducted in 2017, 2018 and 2019. By clicking the button below, you will find the results to date for the 2019 PAMA Impact Survey.
Near Patient Testing
